We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gut Microbes Differ Between Two Common Conditions

By LabMedica International staff writers
Posted on 01 Jan 2019
Print article
Image: A colored scanning electron micrograph (SEM) of Faecalibacterium prausnitzii, one of the most abundant anaerobic bacteria in the human gut microbiota, and its relative abundance is a biomarker of intestinal health in adults (Photo courtesy of BioFoundations).
Image: A colored scanning electron micrograph (SEM) of Faecalibacterium prausnitzii, one of the most abundant anaerobic bacteria in the human gut microbiota, and its relative abundance is a biomarker of intestinal health in adults (Photo courtesy of BioFoundations).
Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are two of the most common diseases of the gastrointestinal tract. Unlike IBD, IBS does not cause inflammation, ulcers or other damage to the bowel.

Instead, IBS is a much less serious problem called a functional disorder. This means that the digestive system looks normal but does not work as it should. Symptoms of IBS may include cramps, bloating, gas, diarrhea, constipation and mucus in the stool. IBS has also been called spastic colon or spastic bowel.

An international team of scientists led by the University of Groningen (Groningen, Netherlands) performed metagenomic sequencing on stool samples from 355 individuals with IBD (Crohn's disease or ulcerative colitis), 412 individuals with IBS, and 1,025 unaffected, healthy controls, searching for microbial species and strains associated with one or both inflammatory gut conditions.

The team performed shotgun metagenomic sequencing used Illumina instruments on microbial DNA in home-collected stool samples from 1,792 well-phenotyped cases and controls from three cohorts from the Netherlands. The team's sequence data led to 219 Crohn's disease-related taxa, 102 taxa associated with ulcerative colitis, and 66 taxa with apparent ties to IBS. There was some overlap between conditions: Within IBD, for example, at least 87 of the microbes implicated in ulcerative colitis also turned up in individuals with Crohn's disease.

The scientist noted that the diversity of strains within beneficial bacterial species, such as Faecalibacterium prausnitzii, tended to wane in the guts of individuals with IBD or IBS relative to the unaffected controls. They also saw shifts in strain diversity for 21 bacterial species in individuals with Crohn's disease, compared to strain diversity changes in 15 species in those with ulcerative colitis and one species in the IBS group. The team also estimated growth rates for a subset of the gut microbial species, identifying small sets of species that seemed to have altered abundance in each of the conditions. In addition, they investigated the differences in bacterial composition, gene content, and gene functions in the IBD and IBS cases.

The authors concluded that despite substantial overlap between the gut microbiome of patients with IBD and IBS compared with control individuals, they were able to use gut microbiota composition differences to distinguish patients with IBD from those with IBS. By combining species-level profiles and strain-level profiles with bacterial growth rates, metabolic functions, antibiotic resistance, and virulence factor analyses, they identified key bacterial species that may be involved in two common gastrointestinal diseases. The study was published on December 19, 2018, in the journal Science Translational Medicine.

Related Links:
University of Groningen

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.